Prenetics Global Limited (NASDAQ:PRE – Get Free Report) CFO Brian Rosin purchased 5,100 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was bought at an average price of $22.80 per share, for a total transaction of $116,280.00. Following the transaction, the chief financial officer directly owned 23,100 shares of the company’s stock, valued at $526,680. This trade represents a 28.33% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
Prenetics Global Stock Up 10.9%
PRE stock opened at $25.78 on Thursday. Prenetics Global Limited has a 52 week low of $7.27 and a 52 week high of $26.29. The business has a 50-day simple moving average of $19.24 and a 200 day simple moving average of $18.98. The company has a market cap of $434.91 million, a PE ratio of -6.20 and a beta of 0.26.
Prenetics Global (NASDAQ:PRE – Get Free Report) last announced its quarterly earnings data on Wednesday, August 19th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.31. The firm had revenue of $46.49 million for the quarter, compared to the consensus estimate of $49.85 million. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. On average, analysts anticipate that Prenetics Global Limited will post -1.86 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on PRE
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Operose Advisors LLC acquired a new stake in shares of Prenetics Global during the 2nd quarter valued at $129,000. Renaissance Technologies LLC raised its position in Prenetics Global by 85.1% in the first quarter. Renaissance Technologies LLC now owns 31,322 shares of the company’s stock valued at $605,000 after purchasing an additional 14,400 shares during the last quarter. State of Wyoming bought a new position in Prenetics Global in the first quarter valued at about $48,000. Stevens Capital Partners boosted its stake in shares of Prenetics Global by 54.6% during the first quarter. Stevens Capital Partners now owns 28,147 shares of the company’s stock valued at $544,000 after purchasing an additional 9,940 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in shares of Prenetics Global during the fourth quarter valued at about $468,000. 25.01% of the stock is currently owned by institutional investors.
Prenetics Global Company Profile
Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.
Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.
Recommended Stories
- Five stocks we like better than Prenetics Global
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
